Patent Application
20230054690
This application relates generally to injectrodes.
Chronic back pain affects millions of people. One approach to treating chronic back pain is through neuromodulation to damage or destroy the spinal nerves that carry the pain impulses to the brain. Another approach is to stimulate these spinal nerves.
A recent focus of treating chronic back pain is the dorsal root ganglia (DRG) 10, which is illustrated schematically in
Example embodiments described herein have innovative features, no single one of which is indispensable or solely responsible for their desirable attributes. The following description and drawings set forth certain illustrative implementations of the disclosure in detail, which are indicative of several exemplary ways in which the various principles of the disclosure may be carried out. The illustrative examples, however, are not exhaustive of the many possible embodiments of the disclosure. Without limiting the scope of the claims, some of the advantageous features will now be summarized. Other objects, advantages and novel features of the disclosure will be set forth in the following detailed description of the disclosure when considered in conjunction with the drawings, which are intended to illustrate, not limit, the invention.
An aspect of the invention is directed to an apparatus comprising: an elongated body having a tapered distal end and a proximal end that are aligned along an axis; first and second electrical sensors disposed on the elongated body; an injection port on the elongated body between the first and second electrical sensors; a power source electrically coupled to the first and second electrical sensors; a computer having an input electrically coupled to the first and second electrical sensors to receive first and second output signals, respectively, from the first and second electrical sensors; and a non-transitory computer-readable memory operatively coupled to the computer, the non-transitory computer-readable memory storing computer-readable instructions that, when executed by the computer, cause the computer to: analyze an electrical characteristic measured by the first and second electrical sensors; and produce an output control signal when the electrical characteristic measured by the first and second electrical sensors indicates that the injection port is aligned with a target anatomical feature.
In one or more embodiments, the apparatus further comprises a reservoir disposed in the body and in fluid communication with the injection port, the reservoir configured to hold a chemical therapeutic agent, the chemical therapeutic agent configured to damage one or more nerves in the target anatomical feature. In one or more embodiments, the apparatus further comprises an electromechanical valve disposed between the reservoir and the injection port. In one or more embodiments, the electromechanical valve is in electrical communication with the computer, the electromechanical valve having a default closed state in which the reservoir is fluidly decoupled from the injection port and an open state in which the reservoir is fluidly coupled to the injection port, the electromechanical valve configured to transition from the default closed state to the open state in response to the output control signal.
In one or more embodiments, the injection port is aligned with the target anatomical feature when the electrical characteristic measured by the first and second electrical sensors has about the same magnitude. In one or more embodiments, the injection port is aligned with the target anatomical feature when the electrical characteristic measured by the first and second electrical sensors indicates that the first and second electrical sensors are in physical contact with the target anatomical feature.
In one or more embodiments, the injection port is aligned with the target anatomical feature when the magnitude of the electrical characteristic measured by the first and second electrical sensors is higher than a respective baseline magnitude. In one or more embodiments, the first electrical sensor is located closer to the tapered distal end than the second electrical sensor, and the injection port is aligned with the target anatomical feature when the electrical characteristic measured by the first electrical sensor indicates that the first electrical sensor has passed over the target anatomical feature and the electrical characteristic measured by the second electrical sensor indicates that the second electrical sensor is not in physical contact with the target anatomical feature.
In one or more embodiments, the electrical characteristic comprises a resistance or an impedance. In one or more embodiments, the proximal end is flared.
Another aspect of the invention is directed to a method comprising: inserting an apparatus into a mammalian subject, the apparatus comprising: an elongated body having a tapered distal end and a proximal end that are aligned along an axis; first and second electrical sensors disposed on the elongated body; and an injection port on the elongated body between the first and second electrical sensors, wherein: the first and second electrical sensors are electrically coupled to a power source, and the first and second electrical sensors are electrically coupled to an input of a computer to receive first and second output signals, respectively, from the first and second electrical sensors. The method further comprises: monitoring, with the computer, an electrical characteristic measured by the first and second electrical sensors; and producing, with the computer, an output control signal when the electrical characteristic measured by the first and second electrical sensors indicates that the injection port is aligned with a target anatomical feature.
In one or more embodiments, the method further comprises automatically injecting a chemical therapeutic agent, through the injection port, in response to the output control signal. In one or more embodiments, the method further comprises opening an electromechanical valve, in response to the output control signal, to fluidly couple the injection port to a reservoir in the apparatus, the reservoir storing the chemical therapeutic agent. In one or more embodiments, the method further comprises damaging at least one nerve in the target anatomical feature.
In one or more embodiments, the method further comprises: determining, with the computer, when a magnitude of the electrical characteristic measured by the first and second electrical sensors is higher than the magnitude of a respective baseline output signal of the first and second electrical sensors; and producing the output control signal when the magnitude of the electrical characteristic measured by the first and second electrical sensors is higher than the magnitude of the respective baseline output signal of the first and second electrical sensors. In one or more embodiments, the method further comprises producing the output control signal when the magnitude of the electrical characteristic measured by the first and second electrical sensors is about the same and higher than the magnitude of the respective baseline output signal of the first and second electrical sensors.
In one or more embodiments, the method further comprises: (a) determining, with the computer, when a magnitude of the electrical characteristic measured by the first electrical sensor is higher than the magnitude of a baseline output signal of the first electrical sensor and the magnitude of the electrical characteristic measured by the second electrical sensor is about equal to the magnitude of a baseline output signal of the second electrical sensor; (b) after step (a), determining, with the computer, when the magnitude of the electrical characteristic measured by the first and second electrical sensors is about equal to the magnitude of the baseline output signals of the first and second electrical sensors, respectively; and (c) producing the output control signal when the magnitude of the electrical characteristic measured by the first and second electrical sensors is about equal to the magnitude of the baseline output signals of the first and second electrical sensors, respectively, wherein the first electrical sensor is located closer to the tapered distal end than the second electrical sensor.
In one or more embodiments, the method further comprises (d) advancing the apparatus distally in the mammalian subject between steps (a) and (b), wherein the apparatus is in a first position in step (a) and in a second position in step (b). In one or more embodiments, the method further comprises: (e) determining, with the computer, when the magnitude of the electrical characteristic measured by the second electrical sensor is higher than the magnitude of the baseline output signal of the second electrical sensor and the magnitude of the electrical characteristic measured by the first electrical sensor is about equal to the magnitude of the baseline output signal of the first electrical sensor; (f) advancing the apparatus distally in the mammalian subject between steps (b) and (e), wherein the apparatus is in a third position in step (e), the second position between the first position and the third position; and (g) retracting the apparatus proximally in the mammalian subject after step (e) to a fourth position, the fourth position between the first position and the third position; (h) after step (g), repeating step (b), wherein step (c) occurs after step (h).
In one or more embodiments, the electrical characteristic comprises a resistance or an impedance.
For a fuller understanding of the nature and advantages of the concepts disclosed herein, reference is made to the detailed description of preferred embodiments and the accompanying drawings.
An injectrode includes a proximal electrical sensor, a distal electrical sensor, and an injection port. The injection port is located between the proximal and distal electrical sensors. The injectrode is configured to be inserted into a mammalian subject (e.g., a human), for example to locate and damage a target neural ganglium (e.g., the DRG). The electrical sensors are configured to measure an electrical characteristic (e.g., resistance or impedance) as the injectrode is inserted into the subject. The electrical characteristic measured by an electrical sensor changes when that electrical sensor comes into physical contact with the target neural ganglium. The electrical characteristic measured by the electrical sensors is used to determine when the injection port is located within and/or aligned with the target neural ganglium.
In one embodiment, the injectrode is configured so that both electrical sensors can simultaneously physically contact the target neural ganglium. In this embodiment, the magnitude of the electrical characteristic measured by both electrical sensors increases compared to a baseline value or magnitude when the electrical sensors are in physically contact with the target neural ganglium, which indicates that the injection port is located within and/or aligned with the target neural ganglium.
In another embodiment, the injectrode is configured so that only one electrical sensor can physically contact the target neural ganglium at any one time. In this embodiment, the magnitude of the electrical characteristic measured by the distal electrical sensor increases compared to a baseline value or magnitude when the distal electrical sensor has physically contacted the target neural ganglium while the magnitude of the electrical characteristic measured by the proximal electrical sensor remains about equal to the baseline magnitude. As the injectrode is inserted further distally, the magnitude of the electrical characteristic measured by the distal electrical sensor returns to about the baseline magnitude and the magnitude of the electrical characteristic measured by the proximal electrical sensor remains about equal to the baseline magnitude, which indicates that the target neural ganglium is located between the distal and proximal electrical sensors and that the injection port is located within and/or aligned with the target neural ganglium.
The distal and proximal electrical sensors are electrically coupled to a power source, which can be internal or external to the injectrode. In addition, the distal and proximal electrical sensors or their wires/leads can be electrically coupled to a computer that can be programmed to monitor the electrical characteristic measured by the distal and proximal electrical sensors and produce an output control signal when the injection port is located within and/or aligned with the target neural ganglium.
The body 300 includes distal and proximal electrical sensors 321, 322 and an injection port 330. The injection port 330 is located between the electrical sensors 321, 322 along the length of the body 300 (e.g., along a longitudinal axis 305 that extends from the distal end 310 to the proximal end 320). The electrical sensors 321, 322 comprise a conductive material that is preferably biocompatible. For example, the electrical sensors 321, 322 can comprise a biocompatible conductive metal such as platinum or a biocompatible conductive polymer such as a polythiophene (e.g., poly(3,4-ethylenedioxythiophene) (PEDOT)). The electrical sensors 321, 322 are electrically coupled to one or more power sources 340 via respective wires or leads 345 that can extend through and/or be disposed in the proximal end 320 of the injectrode 30. The power source(s) 340 can apply an AC or DC voltage across the positive and negative terminals of each electrical sensor 321, 322. The power source(s) 340 can be an external power source or supply, as illustrated in
The electrical characteristics measured by the electrical sensors 321, 322 can change when the electrical sensors 321, 322 are electrically coupled to different materials. For example, the effective resistance or impedance across the positive and negative terminals of each electrical sensor 321, 322 can vary as the electrical sensors 321, 322 are inserted into the surgical site and placed in physical contact with different anatomical features and substances. The effective resistance or impedance across the positive and negative terminals of the electrical sensor 321, 322 can be relatively low when the electrical sensor 321, 322 is in physical contact with a bodily fluid (e.g., blood) and can be relatively high when the electrical sensor 321, 322 is in physical contact a nerve such as the DRG. Alternatively, the effective resistance or impedance across the positive and negative terminals of the electrical sensor 321, 322 can be relatively high when the electrical sensor 321, 322 is in physical contact with a bodily fluid (e.g., blood) and can be relatively low when the electrical sensor 321, 322 is in physical contact a nerve such as the DRG. Thus, the electrical characteristics measured by the electrical sensors 321, 322 can change when one or both electrical sensors 321, 322 are in physical contact with the DRG, which can indicate when the injection port 330 is positioned in the DRG.
A computer or controller 360 can be electrically coupled to the wires or leads 345 to determine the electrical characteristics (e.g., resistance, impedance, and/or another electrical characteristic) measured by the electrical sensors 321, 322. Additional electrical sensors can be included in other embodiments. Additionally or alternatively, the electrical sensors 321, 322 can be in wireless communication with the computer 360. For example, the electrical sensors 321, 322 and computer 360 can each include a short-range wireless transceiver and antenna that can be compatible and/or support Bluetooth.
When the injection port 330 is positioned in the DRG, a chemical therapeutic agent can be injected into the DRG through injection port 330. The chemical therapeutic agent can be stored in a cavity or reservoir 350 that is fluidly coupled to the injection port 330, such as through a tube 352. The reservoir is disposed in the injectrode 30 such as in the body 300. The chemical therapeutic agent can include a chemical agent, a viral agent, and/or another therapeutic substance such as a genetic-altering (e.g., modulating) agent, a protein-altering (e.g., modulating) agent, and/or a cellular-altering (e.g., modulating) agent. The chemical therapeutic agent can damage or disable some or all nerves in the DRG 10, which can prevent the DRG 10 from transmitting sensory signals to the brain or can limit the magnitude of the sensory signals transmitted to the brain (e.g., to prevent or limit the transmission of pain or other negative sensory signals to the brain).
In one embodiment, the electrical sensors 321, 322 are spaced apart along the longitudinal axis 305 such that both electrical sensors 321, 322 can be in physical contact simultaneously with the DRG 10, for example as illustrated in
Plot line 622 increases in magnitude at time C (after time A), which corresponds to the start of physical contact between a portion of proximal electrical sensor 322 and a portion of the DRG 10. Plot line 622 has an increased value (e.g., increased magnitude) and is at a plateau at time D, which indicates that the proximal electrical sensor 322 is in full physical contact with the DRG 10. From time D to time E, both plot lines 621, 622 remain at the plateau indicating that both electrical sensors 321, 322 are in full physical contact with the DRG 10 over this time period
Plot line 621 decreases at time E, which indicates that a portion of distal electrical sensor 321 is not in physical contact with the DRG 10. At time F, plot line 621 has returned to the baseline value or magnitude which indicates that the distal electrical sensor 321 is not in partial or full contact with the DRG 10. In other words, the distal electrical sensor 321 has passed through the DRG 10 at time F. Plot line 622 decreases at time G, which indicates that a portion of proximal electrical sensor 322 is not in physical contact with the DRG 10. At time H, plot line 622 has returned to the baseline value or magnitude which indicates that the proximal electrical sensor 322 is not in partial or full contact with the DRG 10. The proximal electrical sensor 322 has passed through the DRG 10 at time H.
It is noted that although graph 60 indicates that the measured electrical characteristic increases in magnitude when an electrical sensor is physical contact with the DRG, in other embodiments, the measured electrical characteristic can decrease in magnitude when the electrical sensor is physical contact with the DRG. The electrical characteristic can comprise electrical resistance, electrical conductivity, electrical impedance, or another electrical characteristic.
The time interval from time C to time F in graph 60 corresponds to the time interval when it can be determined from the plot lines 621, 622 that the injection port 330, in the embodiment illustrated in
In another embodiment, the electrical sensors 321, 322 are spaced further apart along the longitudinal axis 305 such that only one electrical sensor 321, 322 can be in physical contact with the DRG at any given time, for example as illustrated in
Plot line 822 remains at the baseline value or magnitude from time 0 until time E when plot line 822 increases in magnitude, which corresponds to the start of physical contact between a portion of proximal electrical sensor 322 and a portion of the DRG 10. The time interval between time D and time E corresponds to the time when the proximal electrical sensor 322 has passed through the DRG 10 but the proximal electrical sensor 322 has not physically contacted the DRG 10. Thus, the distal electrical sensor 321 is on the distal side of the DRG 10 and the proximal electrical sensor 322 is on the proximal side of the DRG 10 during this time interval.
From time F to time G, plot line 822 has an increased value or magnitude and is at a plateau, which indicates that the proximal electrical sensor 322 is in full physical contact with the DRG 10 during this time interval. At time G, the plot line 822 decreases in magnitude, which indicates that a portion of proximal electrical sensor 322 is not in physical contact with the DRG 10. At time H, plot line 822 returns to the baseline value or magnitude which indicates that the proximal electrical sensor 322 is not in full or partial physical contact with the DRG 10. Thus, at time H the proximal electrical sensor 322 has fully passed through the DRG 10.
It is noted that although graph 80 indicates that the measured electrical characteristic increases in magnitude when an electrical sensor is physical contact with the DRG, in other embodiments, the measured electrical characteristic can decrease in magnitude when the electrical sensor is physical contact with the DRG. The electrical characteristic can comprise electrical resistance, electrical conductivity, electrical impedance, or another electrical characteristic.
The time interval from time D to time E in graph 80 corresponds to the time interval when it can be determined from the plot lines 821, 822 that the injection port 330, in the embodiment illustrated in
In either embodiment, the computer 360 can be programmed (e.g., in instructions stored in non-volatile memory that is operably coupled to the computer 360 such as operably coupled to a microprocessor of the computer 360) to generate an output control signal to indicate when the injectrode 30 is positioned in the injection window 600, 800 such that the injection port 330 is located in and/or aligned with the DRG. The output control signal can include an audible signal, a visual signal, a haptic signal, and/or other feedback signal to the user. In some embodiments, the injectrode 30 can include an electrical or electromechanical interlock that prevents the injection port from activating until and/or unless the injectrode 30 is positioned in the injection window. For example, an electromechanical valve 900 can be disposed between and fluidly coupled to the reservoir 350 and the injection port 330, as illustrated in
In addition to the above, the electrical sensors 321, 322 can measure or detect a sensory signal in the DRG which can be used to confirm that one or both electrical sensors 321, 322 are positioned in the DRG and not in another anatomical feature. When the injectrode 30 is positioned in an anatomical feature that the operator believes is the DRG, the operator (or another person) can produce a sensory signal by mechanically stimulating (e.g., by touching or stroking) and/or electrically stimulating (e.g., using an electrode) the shin or fingers of the subject, which can cause electrical signals to pass through the sensory nerves in the DRG. If one or both electrical sensors 321, 322 detects these electrical signals, it can be determined that the electrical sensor(s) is/are located in the DRG. If neither electrical sensor detects the electrical signals, then it can be determined that the electrical sensors are not located in the DRG.
In some situations, more than one DRG can be connected to the anatomical feature where the subject feels pain (or other undesired sensory signal). In these situations, damaging/disabling one DRG may not remove (or fully remove) the subject’s pain symptoms. To make sure that all DRGs associated with the subject’s pain symptoms are treated, the injectrode 30 can be used to inject a temporary numbing agent (e.g., via injection port 330 or another port), such as lidocaine, into a DRG after the operator confirms that the DRG contributes to carrying the undesirable pain signals to the brain. The operator can confirm that the DRG contributes to carrying the undesirable pain signals by mechanically and/or electrically stimulating the location on the subject’s body where pain is felt and then detecting/measuring any corresponding electrical signals in the patient’s spinal cord. After the DRG is temporarily numbed with lidocaine, the operator can restimulate the same location on the subject’s body to determine if corresponding electrical signals are still detected in the patient’s spinal cord. If electrical signals in the patient’s spinal cord are still detected in response to the second stimulation, the operator can confirm that a second DRG may need to be treated. When the operator locates another DRG, the operator can confirm whether the second DRG contributes to carrying the undesirable pain signals using the same procedure as in the first DRG. If the operator confirms that the second DRG contributes to carrying the undesirable pain signals, the second DRG can be temporarily numbed with lidocaine. Then the operator can restimulate the same location on the subject’s body to determine if any corresponding electrical signals are detected in the patient’s spinal cord. If such electrical signals are detected, the process repeats (additional DRGs are located and temporarily numbed) until the stimulation does not induce electrical signals in the patient’s spinal cord. When no electrical signals are induced in the spinal cord in response to simulating the location on the subject’s body, the operator can confirm that he/she has located all DRGs that contribute to carrying the undesirable pain signals to the brain. These DRG(s) can then be treated with a chemical therapeutic agent, as described above.
In addition to DRGs, the device and method can be used in other neural ganglia (facial ganglia, stellate ganglia, nodose ganglia, etc.), in brain targets (e.g., Parkinson’s-knowing physiologically that you are in a specific location of the target, epilepsy, etc.), and/or in other tissues of the body based on electrical properties (e.g., in a specific part of liver, in a vein and out or through the vein, subcutaneous -v-intramuscular, etc.).
In step 1002, power is supplied to the electrical sensors 321, 322 on the injectrode. The power can be supplied from an internal or external power source, such as power source(s) 340. The power can be AC power or DC power, which can produce an AC voltage or a DC voltage, respectively, across the positive and negative electrical terminals of each electrical sensor 321, 322.
In step 1003, one or more electrical characteristics measured by the electrical sensors 321, 322 is/are monitored with a computer 360 that is electrically coupled to the electrical sensors 321, 322. For example, the computer 360 can be electrically coupled to the wires or leads 345 that electrically couple the power source(s) 340 to the electrical sensors 321, 322. Additionally or alternatively, the computer 360 can be in wireless communication with the electrical sensors 321, 322.
In step 1004, the computer 360 produces an output control signal when the computer determines that the electrical characteristic(s) measured by the electrical sensors 321, 322 correspond to an injection window (e.g., injection window 600 or injection window 800) in which the injection port 330 is aligned with and/or located in the neural ganglia (e.g., DRG). The output control signal can include or produce one or more sensory output signals in step 1005 to alert a user or operator. For example, the output control signal can include an output audio signal, an output video/graphical signal, and/or an output haptic signal. Additionally or alternatively, the output control signal can cause the injectrode 30 to automatically inject a chemical therapeutic agent through the injection port 330 in step 1006, which can damage one or more nerves in the target neural ganglium. Additionally or alternatively, the output control signal can cause an electromechanical valve (e.g., electromechanical valve 900) to open in step 1007 to fluidly couple the injection port 330 to the reservoir 350, which can allow the chemical therapeutic agent to be injected through the injection port 330. Additionally or alternatively, the output control signal can cause an interlock to be released in step 1007 to allow the chemical therapeutic agent to be injected through the injection port 330.
In some embodiments, the operator (or another person) can produce a sensory signal by mechanically stimulating (e.g., by touching or stroking) and/or electrically stimulating (e.g., using an electrode) the shin or fingers of the subject in step 1008, which can cause electrical signals to pass through the sensory nerves in the DRG. If one or both electrical sensors 321, 322 detects these electrical signals, it can be determined that the electrical sensor(s) is/are located in the DRG. If neither electrical sensor detects the electrical signals, then it can be determined that the electrical sensors are not located in the DRG.
Steps 1001-1003 can occur simultaneously such that the injectrode is inserted and being positioned while power is supplied to the electrical sensors and the measured electrical characteristic(s) are being monitored.
During steps 1001-1003, the injectrode of
When the injectrode has the configuration of
During steps 1001-1003, the injectrode of
In optional step 1010 (via placeholder A), the injectrode is advanced distally from the second position to a third position where the proximal electrical sensor 322 is in physical contact with the target neural ganglium (e.g., DRG 10) and the distal electrical sensor 321 is not in physical contact with the target neural ganglium, as illustrated in
This disclosure should not be considered limited to the particular embodiments described above. Various modifications, equivalent processes, as well as numerous structures to which the present invention may be applicable, will be readily apparent to those skilled in the art to which the invention is directed upon review of this disclosure. The above-described embodiments may be implemented in numerous ways. One or more aspects and embodiments involving the performance of processes or methods may utilize program instructions executable by a device (e.g., a computer, a processor, or other device) to perform, or control performance of, the processes or methods.
In this respect, various inventive concepts may be embodied as a non-transitory computer readable storage medium (or multiple non-transitory computer readable storage media) (e.g., a computer memory of any suitable type including transitory or non-transitory digital storage units, circuit configurations in field programmable gate arrays (FPGAs) or other semiconductor devices, or other tangible computer storage medium) encoded with one or more programs that, when executed on one or more computers or other processors, perform methods that implement one or more of the various embodiments described above. When implemented in software (e.g., as an app), the software code may be executed on any suitable processor or collection of processors, whether provided in a single computer or distributed among multiple computers.
Further, it should be appreciated that a computer may be embodied in any of a number of forms, such as a rack-mounted computer, a desktop computer, a laptop computer, or a tablet computer, as non-limiting examples. Additionally, a computer may be embedded in a device not generally regarded as a computer but with suitable processing capabilities, including a personal digital assistant (PDA), a smartphone or any other suitable portable or fixed electronic device.
Also, a computer may have one or more communication devices, which may be used to interconnect the computer to one or more other devices and/or systems, such as, for example, one or more networks in any suitable form, including a local area network or a wide area network, such as an enterprise network, an intelligent network, or the Internet. Such networks may be based on any suitable technology and may operate according to any suitable protocol and may include wireless networks or wired networks.
Also, a computer may have one or more input devices and/or one or more output devices. These devices can be used, among other things, to present a user interface. Examples of output devices that may be used to provide a user interface include printers or display screens for visual presentation of output and speakers or other sound generating devices for audible presentation of output. Examples of input devices that may be used for a user interface include keyboards, and pointing devices, such as mice, touch pads, and digitizing tablets. As another example, a computer may receive input information through speech recognition or in other audible formats.
The non-transitory computer readable medium or media may be transportable, such that the program or programs stored thereon may be loaded onto one or more different computers or other processors to implement various one or more of the aspects described above. In some embodiments, computer readable media may be non- transitory media.
The terms “program,” “app,” and “software” are used herein in a generic sense to refer to any type of computer code or set of computer-executable instructions that may be employed to program a computer or other processor to implement various aspects as described above. Additionally, it should be appreciated that, according to one aspect, one or more computer programs that when executed perform methods of the present application need not reside on a single computer or processor, but may be distributed in a modular fashion among a number of different computers or processors to implement various aspects of the present application.
Computer-executable instructions may be in many forms, such as program modules, executed by one or more computers or other devices. Generally, program modules include routines, programs, objects, components, data structures, etc. that performs particular tasks or implement particular abstract data types. The functionality of the program modules may be combined or distributed as desired in various embodiments.
Also, data structures may be stored in computer-readable media in any suitable form. For simplicity of illustration, data structures may be shown to have fields that are related through location in the data structure. Such relationships may likewise be achieved by assigning storage for the fields with locations in a computer-readable medium that convey relationship between the fields. However, any suitable mechanism may be used to establish a relationship between information in fields of a data structure, including through the use of pointers, tags or other mechanisms that establish relationship between data elements.
Thus, the present disclosure includes new and novel improvements to existing methods and technologies, which were not previously known nor implemented to achieve the useful results described above. Users of the present method and system will reap tangible benefits from the functions now made possible on account of the specific modifications described herein causing the effects in the system and its outputs to its users. It is expected that significantly improved operations can be achieved upon implementation of the invention.
Also, as described, some aspects may be embodied as one or more methods. The acts performed as part of the method may be ordered in any suitable way. Accordingly, embodiments may be constructed in which acts are performed in an order different than illustrated, which may include performing some acts simultaneously, even though shown as sequential acts in illustrative embodiments.
This application claims priority to U.S. Provisional Application No. 63/260,376, filed Aug. 18, 2021, titled “Injectrode With Multiple Electrical Sensors,” which is hereby incorporated by reference.
| Number | Date | Country | |
|---|---|---|---|
| 63260376 | Aug 2021 | US |
